OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027
OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026
FDA Clearance of IND for OPGx-RDH12, with Phase 1/2 Trial Dosing Planned for Q4 2026
FDA Approval of Phentolamine Ophthalmic Solution 0.75% for Presbyopia Triggers Milestone Payment
Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers
“The last several months have marked a period of tremendous advancement for our leading gene therapy programs,” said
“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams. With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases,” concluded
Pipeline Updates
OPGx-BEST1
- Announced positive 3- and 6-month results from the low-dose Cohort 1 of the Phase 1/2 BIRD-1 trial, with a favorable safety profile and no serious adverse events or dose-limiting toxicities.
- All five participants demonstrated clinically meaningful improvement in visual function, including retinal sensitivity improvement by microperimetry in 75% of evaluable participants (3/4), and four of five showed structural improvements.
- Aligned with the FDA on a potential pivotal endpoint of =3 dB microperimetry improvement in =5 prespecified loci, in conjunction with a patient-reported outcome.
- Completed enrollment and dosing of 11 participants in the high-dose Cohort 2, with topline data, including 3-month data from Cohort 2 and 6-month data for the three Cohort 1 participants with Best vitelliform macular dystrophy, expected in Q1 2027.
OPGx-LCA5
- The registrational Phase 3 trial is fully enrolled with 8 participants, and initiation of dosing is expected in Q4 2026.
- Phase 1/2 data presented at Retina in Rio 2026 showed sustained improvements in visual acuity and light sensitivity in adults through 24 months and encouraging results in pediatric participants through six months.
OPGx-RDH12
- Received FDA clearance of the Investigational New Drug (IND) application for OPGx-RDH12 for RDH12-associated Leber congenital amaurosis (RDH12-LCA), with initiation of dosing in a Phase 1/2 trial expected in Q4 2026.
Phentolamine Ophthalmic Solution 0.75%
- Received FDA approval of the supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% (RYZUMVI®) for the treatment of presbyopia in adults, triggering a regulatory milestone payment to
Opus Genetics from commercial partner, Viatris Inc.
Recent Medical Presentations
Management Team
Financial Results for the Third Quarter Ended
Cash Position: As of
Revenue: License and collaborations revenue totaled
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss for the quarter ended
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to the Company’s continued clinical development, clinical results, preclinical data, and future plans for its product candidates, including the anticipated timing of initiation of clinical trials, dosing completion, data results; the Company’s development strategy for its product candidates; the outcome of the Company’s ongoing regulatory interactions with the FDA and its expectations regarding the design of, and potential endpoints for, its planned clinical trials of its product candidates; the therapeutic potential of the Company’s product candidates; the Company’s expectations regarding its cash runway, future financing availability and potential future funding under the Oberland facility, and the anticipated sufficiency of the Company’s cash runway to enable it to achieve multiple clinical inflection points and opportunities for priority review vouchers; and the Company’s expectations regarding its business prospects and results of operations. The forward-looking statements contained herein are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in the Company’s other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
| -Financial Tables Follow- | |||||||
Condensed Consolidated Balance Sheets (in thousands, except share amounts and par value) | |||||||
| As of | |||||||
2026 | 2025 | ||||||
| Assets | (Unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 88,974 | $ | 45,091 | |||
| Accounts receivable | 1,005 | 1,995 | |||||
| Contract assets and unbilled receivables | 628 | 1,170 | |||||
| Prepaids and other current assets | 4,249 | 1,788 | |||||
| Total current assets | 94,856 | 50,044 | |||||
| Property and equipment, net | 339 | 199 | |||||
| Restricted cash | 100 | — | |||||
| Total assets | $ | 95,295 | $ | 50,243 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,727 | $ | 3,293 | |||
| Accrued expenses | 6,105 | 4,488 | |||||
| Total current liabilities | 9,832 | 7,781 | |||||
| Long-term debt | 34,530 | — | |||||
| Warrant liabilities | 11,151 | 25,985 | |||||
| Funding agreement, related party | 1,351 | 1,129 | |||||
| Total liabilities | 56,864 | 34,895 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, par value | — | — | |||||
| Common stock, par value | 10 | 7 | |||||
| Additional paid-in capital | 346,032 | 203,930 | |||||
| Accumulated other comprehensive income | 1,106 | — | |||||
| Accumulated deficit | (308,717 | ) | (188,589 | ) | |||
| Total stockholders’ equity | 38,431 | 15,348 | |||||
| Total liabilities and stockholders’ equity | $ | 95,295 | $ | 50,243 | |||
Condensed Consolidated Statements of Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) | |||||||||||||||
| For the Three Months Ended | For the Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| License and collaborations revenue | $ | 1,137 | $ | 3,079 | $ | 4,049 | $ | 10,331 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 14,494 | 6,409 | 36,278 | 20,384 | |||||||||||
| General and administrative | 5,890 | 4,981 | 17,862 | 17,093 | |||||||||||
| Total operating expenses | 20,384 | 11,390 | 54,140 | 37,477 | |||||||||||
| Loss from operations | (19,247 | ) | (8,311 | ) | (50,091 | ) | (27,146 | ) | |||||||
| Fair value change in instruments measured at fair value | (28,610 | ) | (9,525 | ) | (72,800 | ) | (5,803 | ) | |||||||
| Financing costs | — | — | (1,113 | ) | (1,337 | ) | |||||||||
| Other income, net | 1,362 | 382 | 3,876 | 1,218 | |||||||||||
| Loss before income taxes | (46,495 | ) | (17,454 | ) | (120,128 | ) | (33,068 | ) | |||||||
| Benefit (provision) for income taxes | — | — | — | — | |||||||||||
| Net loss | (46,495 | ) | (17,454 | ) | (120,128 | ) | (33,068 | ) | |||||||
| Change in fair value of the Notes attributable to instrument specific credit risk | 1,106 | — | 1,106 | — | |||||||||||
| Comprehensive loss | $ | (45,389 | ) | $ | (17,454 | ) | $ | (119,022 | ) | $ | (33,068 | ) | |||
| Net loss per share: | |||||||||||||||
| Basic and diluted | $ | (0.46 | ) | $ | (0.25 | ) | $ | (1.27 | ) | $ | (0.59 | ) | |||
| Number of shares used in per share calculations: | |||||||||||||||
| Basic and diluted | 101,841,608 | 70,636,887 | 94,793,509 | 56,100,689 | |||||||||||
Source:
Source: 